Author

E. B. Kabotyanski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

C. Hamor· 1 shared C. M. Perou· 1 shared C. Montemayor-Garcia· 1 shared D. Acosta· 1 shared E. Villegas· 1 shared J. H. Shepherd· 1 shared J. M. Rosen· 1 shared L. E. Dobrolecki· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

C. Hamor

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

Y. Gao, E. B. Kabotyanski, E. Villegas, J. H. Shepherd, D. Acosta, C. Hamor, T. Sun, C. Montemayor-Garcia, X. He, L. E. Dobrolecki, T. F. Westbrook, M. T. Lewis, S. G. Hilsenbeck, X. H.- F. Zhang, C. M. Perou, J. M. Rosen

This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.

bioRxiv · Jun 16, 2021Cancer Biology